ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Erasca, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$13.62+0.23 (+1.72%)
Close on Oct 19, 2026
- Market cap
- $4.24B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
+$11.20 (+462.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $4.24B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 11.72
- Dividend yield
- 0.00%
- Free cash flow yield
- -2.31%
Fundamentals
- Net income
- -$287.22M
- EPS, diluted
- -$0.95
- Free cash flow
- -$98.08M
- Book value per share
- $1.16
- Diluted shares
- 311M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$302.68M
Net income
-$287.22M
EPS, diluted
-$0.95
Free cash flow
-$98.08M
Reported periodTrailing twelve months